Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care

B. Germaná; F. Di Mario; L. G. Cavallaro; A. M. Moussa; P. Lecis; S. Liatoupolou; G. Comparato; C. Carloni; G. Bertiato; M. Battiestel; N. Papa; G. Aragona; G. M. Cavestro; V. Iori; R. Merli; S. Bertolini; P. Caruana; A. Franzé

doi:10.1016/j.dld.2005.01.016

Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care

B. Germaná, F. Di Mario, L. G. Cavallaro, A. M. Moussa, P. Lecis, S. Liatoupolou, G. Comparato, C. Carloni, G. Bertiato, M. Battiestel, N. Papa, G. Aragona, G. M. Cavestro, V. Iori, R. Merli, S. Bertolini, P. Caruana, A. Franzé

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.

Original language	English
Pages (from-to)	501-508
Number of pages	8
Journal	Digestive and Liver Disease
Volume	37
Issue number	7
DOIs	https://doi.org/10.1016/j.dld.2005.01.016
Publication status	Published - Jul 2005

Keywords

Chronic gastritis
Dyspeptic patients
Gastrin-17
IgG anti-H. pylori
Serum pepsinogens

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.dld.2005.01.016

Fingerprint Dive into the research topics of 'Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care'. Together they form a unique fingerprint.

Cite this

Germaná, B., Di Mario, F., Cavallaro, L. G., Moussa, A. M., Lecis, P., Liatoupolou, S., Comparato, G., Carloni, C., Bertiato, G., Battiestel, M., Papa, N., Aragona, G., Cavestro, G. M., Iori, V., Merli, R., Bertolini, S., Caruana, P., & Franzé, A. (2005). Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. Digestive and Liver Disease, 37(7), 501-508. https://doi.org/10.1016/j.dld.2005.01.016

Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. / Germaná, B.; Di Mario, F.; Cavallaro, L. G.; Moussa, A. M.; Lecis, P.; Liatoupolou, S.; Comparato, G.; Carloni, C.; Bertiato, G.; Battiestel, M.; Papa, N.; Aragona, G.; Cavestro, G. M.; Iori, V.; Merli, R.; Bertolini, S.; Caruana, P.; Franzé, A.

In: Digestive and Liver Disease, Vol. 37, No. 7, 07.2005, p. 501-508.

Research output: Contribution to journal › Article › peer-review

Germaná, B, Di Mario, F, Cavallaro, LG, Moussa, AM, Lecis, P, Liatoupolou, S, Comparato, G, Carloni, C, Bertiato, G, Battiestel, M, Papa, N, Aragona, G, Cavestro, GM, Iori, V, Merli, R, Bertolini, S, Caruana, P & Franzé, A 2005, 'Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care', Digestive and Liver Disease, vol. 37, no. 7, pp. 501-508. https://doi.org/10.1016/j.dld.2005.01.016

Germaná, B. ; Di Mario, F. ; Cavallaro, L. G. ; Moussa, A. M. ; Lecis, P. ; Liatoupolou, S. ; Comparato, G. ; Carloni, C. ; Bertiato, G. ; Battiestel, M. ; Papa, N. ; Aragona, G. ; Cavestro, G. M. ; Iori, V. ; Merli, R. ; Bertolini, S. ; Caruana, P. ; Franzé, A. / Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. In: Digestive and Liver Disease. 2005 ; Vol. 37, No. 7. pp. 501-508.

@article{90943700cc2342e7b9175d3c472e1839,

title = "Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care",

abstract = "Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.",

keywords = "Chronic gastritis, Dyspeptic patients, Gastrin-17, IgG anti-H. pylori, Serum pepsinogens",

author = "B. German{\'a} and {Di Mario}, F. and Cavallaro, {L. G.} and Moussa, {A. M.} and P. Lecis and S. Liatoupolou and G. Comparato and C. Carloni and G. Bertiato and M. Battiestel and N. Papa and G. Aragona and Cavestro, {G. M.} and V. Iori and R. Merli and S. Bertolini and P. Caruana and A. Franz{\'e}",

year = "2005",

month = jul,

doi = "10.1016/j.dld.2005.01.016",

language = "English",

volume = "37",

pages = "501--508",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "Elsevier B.V.",

number = "7",

}

TY - JOUR

T1 - Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care

AU - Germaná, B.

AU - Di Mario, F.

AU - Cavallaro, L. G.

AU - Moussa, A. M.

AU - Lecis, P.

AU - Liatoupolou, S.

AU - Comparato, G.

AU - Carloni, C.

AU - Bertiato, G.

AU - Battiestel, M.

AU - Papa, N.

AU - Aragona, G.

AU - Cavestro, G. M.

AU - Iori, V.

AU - Merli, R.

AU - Bertolini, S.

AU - Caruana, P.

AU - Franzé, A.

PY - 2005/7

Y1 - 2005/7

N2 - Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.

AB - Background.: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. Aim.: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). Patients and methods.: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 ± 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. Results.: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. Conclusion.: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.

KW - Chronic gastritis

KW - Dyspeptic patients

KW - Gastrin-17

KW - IgG anti-H. pylori

KW - Serum pepsinogens

UR - http://www.scopus.com/inward/record.url?scp=26944468729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944468729&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2005.01.016

DO - 10.1016/j.dld.2005.01.016

M3 - Article

C2 - 15975537

AN - SCOPUS:26944468729

VL - 37

SP - 501

EP - 508

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 7

ER -